share_log

NeoGenomics Study Highlights CtDNA's Potential To Predict Recurrence In High-Risk Melanoma; RaDaR Sequencing Assay Identifies Molecular Residual Disease Across Broader Patient Range, Enabling Earlier Detection And Prognosis Monitoring

Benzinga ·  Dec 11 21:08
NeoGenomics Study Highlights CtDNA's Potential To Predict Recurrence In High-Risk Melanoma; RaDaR Sequencing Assay Identifies Molecular Residual Disease Across Broader Patient Range, Enabling Earlier Detection And Prognosis Monitoring
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment